Table 2 The functions and clinical relevance of SIK in tumorigenesis
From: The potent roles of salt-inducible kinases (SIKs) in metabolic homeostasis and tumorigenesis
SIK members | Tumors | Functions | Mechanisms | References |
|---|---|---|---|---|
SIK1 | Brest cancer | Tumor suppressor | Promote the anoikis of cancer cells through LKB1-SIK1-p53 and inhibit metastasis | |
SIK1 | Ovarian cancer | Tumor suppressor | Inhibit proliferation and loss the characteristics of tumor stem cells | |
SIK1/3 | Lung cancer | Tumor suppressor | Couple with LKB1 inhibit proliferation via IL-6 and CRTC | |
SIK1 | Pancreatic cancer | Tumor suppressor | Inhibit cancer metabolic reprograming | |
SIK1 | Pancreatic ductal cancer | Tumor suppressor | Reduce gemcitabine resistance | |
SIK1 | Hepatocellular carcinoma | Tumor suppressor | Delay proliferation and EMT via inhibiting Wnt/β-catenin signal activation | |
SIK1 | Lung cancer | Tumor suppressor | Inhibit EMT and increase radiation therapy | |
SIK1 | Colorectal cancer | Tumor suppressor | Inhibit proliferation and migration | |
SIK2 | Ovarian cancer | Oncogene | Inhibit cell apoptosis and promotes G1/S transformation by regulating centrosome, promote metastasis via boosting EMT and associates PI3K/Akt signaling pathway | |
SIK2 | Prostate cancer | Oncogene | Regulate the cell cycle regulators p21, p27 and Cyclin D | |
SIK2 | Diffuse large B cell lymphoma | Oncogene | Regulate glucose metabolism | |
SIK2 | Triple negative breast cancer | Oncogene | Inhibit autophagy flux | |
SIK2 | Breast cancer | Tumor suppressor | Inhibit the proliferation and migration and Akt activity | |
SIK3 | Ovarian cancer | Oncogene | Couple with promote G1/S process via upregulating cyclinD/E and downregulating p21/p27 | |
SIK3 | Breast cancer | Oncogene | Promote G1/S transformation by increasing the activity of CDK2, enhance migration via upregulating CXCR4 and regulate tumor inflammation microenvironment | |
SIK2/3 | Acute myeloid leukemia | Oncogene | Promote proliferation via SIK-HDAC-MEF2C | |
SIK3 | Ovarian cancer | Tumor suppressor | Low expression associates with poor prognosis and resistance topaclitaxel and cisplatin |
